These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15586352)

  • 21. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of the renin-angiotensin system.
    Cheung BM
    Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J; Krum H
    Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
    Kalantarinia K; Okusa MD
    Curr Diab Rep; 2006 Feb; 6(1):8-16. PubMed ID: 16522275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
    Bavishi C; Bangalore S; Messerli FH
    Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
    Swamy KM; Lin MJ; Sun CM
    Mini Rev Med Chem; 2003 Sep; 3(6):621-31. PubMed ID: 12871164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists.
    Izzo JL; Moser M
    J Clin Hypertens (Greenwich); 2002; 4(6 Suppl 2):11-9, 31. PubMed ID: 12461316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chaugai S; Meng WY; Ali Sepehry A
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):388-404. PubMed ID: 26817632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
    Doggrell SA
    Expert Opin Pharmacother; 2002 Nov; 3(11):1543-56. PubMed ID: 12437489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
    Rastogi A; Rashid M; Wright RF
    J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.